Stock Analysis of Arbutus Biopharma Corp (ABUS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ABUS
Close 1.90
Change 0.0500 / 2.70 %
Volume 996300
Vol Change 458451 / 85.24 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Arbutus Biopharma Corp
PE (TTM)

-2088.83

Very Poor
Price / Book

1145.15

Very Poor
Price / Sales

7005.62

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

318620 K

Enterprise Value

288216 K

ROA (TTM)

-40.28

Very Poor
ROE (TTM)

-54.82

Very Poor
Net Margin (TTM)

-335.39

Very Poor
Revenue

255.11 %

39019.00 K
Net Profit

8.91 %

-69456.00 K
Debt to Equity

0.0027

Excellent
Altman Z Score

-5.50

Very Poor
Quick Ratio

4.69

Very Good
Cash Ratio

4.47

Very Good


Highs/Lows of Arbutus Biopharma Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.84 3.26 % 0.133 % 1.941.7929-Nov-2328-Nov-23
Two Week1.84 3.26 % 1.06 % 1.941.75429-Nov-2316-Nov-23
One Month1.73 9.83 % 10.52 % 1.971.715-Nov-2313-Nov-23
Three Month2.03 6.40 % 1.18 % 2.20081.6911-Sep-2323-Oct-23
Six Months2.5 24.00 % 8.21 % 2.6651.6907-Jun-2323-Oct-23
One year2.39 20.50 % 14.98 % 3.151.6930-Mar-2323-Oct-23
Two year3.14 39.49 % 2.25 % 3.151.6930-Mar-2323-Oct-23
Five year4.77 60.17 % 66.21 % 3.150.821430-Mar-2321-Oct-19
Ten year8.15 76.69 % 152.00 % 31.480.821413-Mar-1421-Oct-19


Technical View of Arbutus Biopharma Corp
RSI

38.21

Neutral
MACD

-0.067

Bearish
ADX

23.83

Bearish
Super Trend

1.97

Mild Bearish
Williams %R

-85.17

Mild Bullish
CCI

-104.44

Mild Bullish


EMA 5

1.75

Neutral
EMA 15

1.80

Mild Bearish
EMA 50

1.94

Strong Bearish
EMA 100

2.09

Strong Bearish
SMA 100

2.10

Strong Bearish
SMA 200

2.44

Strong Bearish
SMA 5 / 20

1.74 / 1.83

Strong Bearish
SMA 15 / 50

1.81 / 1.95

Strong Bearish
SMA 50 / 200

1.95 / 2.44

Strong Bearish




Charts of Arbutus Biopharma Corp


Returns of Arbutus Biopharma Corp with Peers
Period / StockABUSCDMOIMNMHROW
1 Week3.26%-6.62%-5.54%-2.18%
1 Mth9.83%-17.67%-14.09%-34.43%
3 Mth-6.40%-57.49%19.43%-43.53%
6mth-24.00%-66.34%46.48%-55.30%
1 Year-20.50%-65.49%101.07%-16.53%
2 Year-39.49%-83.31%-60.73%-10.01%
5 Years-60.17%-2.50%99.33%


Compare Fundamentals of Arbutus Biopharma Corp with Peers
Ratio / StockABUSCDMOIMNMHROW
PE-2088.83-201.66-533.35-12.03
P/B1145.151.721659.889.36
ROA-40.28-0.354-90.51-11.63
ROE-54.82-0.855-311.22-76.87
Debt To Equity0.00270.7490.01763.80
Revenue39019.00 K
255.11 % 		149266 K
24.81 % 		0
% 		88595.00 K
22.24 %
Net Income-69456.00 K
8.91 % 		3446.00 K
97.30 % 		-37518.00 K
51.83 % 		-14086.00 K
21.77 %


Technicals of Arbutus Biopharma Corp with Peers
Technical / StockABUSCDMOIMNMHROW
ADX11.7733.8028.1932.14
CMF0.309-0.057-0.072-0.174
MFI52.7643.3830.6134.31
RSI55.9835.8334.4830.13
MACD Abv SignalTrueTrueFalseFalse
Price Above 50 MATrueFalseFalseFalse
Price Above 200 MAFalseFalseTrueFalse


About : Arbutus Biopharma Corp

Address : 701 Veterans Circle, Warminster, PA, United States, 18974
Tel : 267 469 0914
URL : https://www.arbutusbio.com
Code : ABUS, ISIN : CA03879J1003, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 03_Aug_2015
Employee Count : 96

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.


Note : All Data Generated at the End of Trading Hours (EOD Data)